Urinary Kallidinogenase for Injection (KLK)

Urinary Kallidinogenase for injection (KLK) is listed in Medical Insurance and Reimbursement List in China.

KLK is the first choice to treat patients with Mild – Moderate Acute Thrombotic Cerebral Infarction, especially, for the patients who miss the treatment window of thrombolytic therapy, which can increases limb function recovery and rehabilitation,  and reduces disability rate.

Reasons to believe:
1. Unique and clear mechanism of action: improve collateral circulation.  2. Adequate fast-onset treatment: 5 minutes after administration, blood flow starts to increase , and the plasma concentration rapidly reaches the peak in 30 minutes. 
3. Long treatment time window: 48 hours. 
4. Increase limb function recovery. 
5. Reduce 72.4% of incidence of moderate – severe disability in long-term outcomes of Patients.